MCID: OVR106
MIFTS: 43

Ovarian Clear Cell Carcinoma

Categories: Cancer diseases, Endocrine diseases, Rare diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Ovarian Clear Cell Carcinoma

MalaCards integrated aliases for Ovarian Clear Cell Carcinoma:

Name: Ovarian Clear Cell Carcinoma 11 14
Clear-Cell Ovarian Carcinoma 11 75

Classifications:



External Ids:

Disease Ontology 11 DOID:0050934

Summaries for Ovarian Clear Cell Carcinoma

Disease Ontology: 11 An ovarian carcinoma that has material basis in cells with clear cytoplasm and glycogen secreting hob nail cells.

MalaCards based summary: Ovarian Clear Cell Carcinoma, also known as clear-cell ovarian carcinoma, is related to endometriosis and clear cell adenocarcinoma. An important gene associated with Ovarian Clear Cell Carcinoma is MIR509-1 (MicroRNA 509-1), and among its related pathways/superpathways are Assembly of the pre-replicative complex and Chromatin organization. The drugs Bevacizumab and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include ovary, lymph node and cervix, and related phenotypes are Increased cell death in HCT116 cells and neoplasm

Wikipedia: 75 Clear cell ovarian carcinoma is one of several subtypes of ovarian carcinoma. Clear cell is a subtype of... more...

Related Diseases for Ovarian Clear Cell Carcinoma

Diseases in the Ovarian Clear Cell Carcinoma family:

Ovarian Small Cell Carcinoma

Diseases related to Ovarian Clear Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 367)
# Related Disease Score Top Affiliating Genes
1 endometriosis 31.9 TP53 PTEN MIR424 HNF1B
2 clear cell adenocarcinoma 31.5 TP53 HNF1B ARID1A
3 serous cystadenocarcinoma 31.1 TP53 PTEN PPP2R1A PIK3CA MIR21 HNF1B
4 ovarian clear cell adenocarcinoma 30.9 TP53 PIK3CA HNF1B H2AC18 ESS2 ARID1A
5 lynch syndrome 30.9 TP53 PTEN PPP2R1A PIK3CA H2AC18 ARID1A
6 ovarian cancer 30.9 ZNF217 TP53 SMARCA4 PTEN PPP2R1A PIK3CA
7 clear cell adenofibroma 30.9 SMARCA4 PIK3CA PBRM1 ARID1A
8 endometriosis of ovary 30.8 PTEN PPP2R1A PIK3CA MIR9-1 MIR424 HNF1B
9 ovarian serous carcinoma 30.7 TP53 MIR509-1 MIR21 H2AC18
10 mismatch repair cancer syndrome 30.7 TP53 PTEN PIK3CA ARID1A
11 inherited cancer-predisposing syndrome 30.6 TP53 SMARCB1 SMARCA4 PTEN
12 bap1 tumor predisposition syndrome 30.6 TP53 SMARCB1 SMARCA4 PTEN
13 malignant teratoma 30.5 TP53 SMARCB1 SMARCA4
14 wilms tumor 1 30.5 TP53 SMARCB1 PTEN H2AC18
15 carcinosarcoma 30.4 TP53 PTEN PPP2R1A PIK3CA
16 endometrial hyperplasia 30.4 TP53 PTEN ARID1A
17 cowden syndrome 30.4 TP53 PTEN PIK3CA MIR21
18 ovarian disease 30.4 TP53 PTEN MIR9-1 MIR424 MIR21 H2AC18
19 intestinal benign neoplasm 30.3 TP53 PTEN PIK3CA MIR21 H2AC18
20 uterine anomalies 30.3 MIR9-1 MIR424 MIR21 HNF1B H2AC18
21 cystadenocarcinoma 30.3 ZNF217 TP53 PTEN MIR21 ARID1A
22 endometrioid ovary carcinoma 30.2 TP53 SMARCA4 PTEN PPP2R1A PIK3IP1 PIK3CA
23 cervical cancer 30.2 TP53 PTEN PIK3CA MIR424 MIR21
24 lung cancer susceptibility 3 30.2 TP53 PPP2R1A PIK3CA MIR9-1 MIR21 H2AC18
25 ewing sarcoma 30.1 TP53 SMARCB1 MIR9-1 H2AC18
26 renal cell carcinoma, nonpapillary 30.0 TP53 PTEN PIK3CA PBRM1 MIR9-1 MIR509-1
27 squamous cell carcinoma, head and neck 29.9 TP53 PTEN PPP2R1A PIK3CA MIR9-1 MIR424
28 epithelial-myoepithelial carcinoma 11.3
29 ovarian epithelial cancer 10.8
30 endometrial cancer 10.6
31 adenocarcinoma 10.5
32 thrombophilia due to thrombin defect 10.5
33 lynch syndrome 1 10.4
34 adenofibroma 10.4
35 high-grade astrocytoma 10.4 TP53 PTEN
36 rete ovarii adenocarcinoma 10.4 PPP2R1A MIR21
37 esophagus verrucous carcinoma 10.4 TP53 PIK3CA
38 vaginal carcinosarcoma 10.4 TP53 PIK3CA
39 clear cell adenocarcinoma of the ovary 10.4
40 granulomatous mastitis 10.4 PTEN MIR21
41 posterior pituitary gland neoplasm 10.4 SMARCB1 SMARCA4
42 breast juvenile papillomatosis 10.4 PTEN PIK3CA ARID1A
43 anal squamous cell carcinoma 10.4 TP53 PIK3CA H2AC18
44 anus cancer 10.4 TP53 PIK3CA H2AC18
45 bartholin's gland adenoid cystic carcinoma 10.4 SMARCA2 PIK3CA ARID1A
46 nonbacterial thrombotic endocarditis 10.4
47 endocarditis 10.4
48 lung oat cell carcinoma 10.4 TP53 PTEN PIK3CA
49 anus disease 10.4 TP53 PIK3CA H2AC18
50 rectal disease 10.4 TP53 PIK3CA H2AC18

Graphical network of the top 20 diseases related to Ovarian Clear Cell Carcinoma:



Diseases related to Ovarian Clear Cell Carcinoma

Symptoms & Phenotypes for Ovarian Clear Cell Carcinoma

GenomeRNAi Phenotypes related to Ovarian Clear Cell Carcinoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death in HCT116 cells GR00103-A-0 8.62 PIK3CA PPP2R1A

MGI Mouse Phenotypes related to Ovarian Clear Cell Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.76 ARID1A PIK3CA PPP2R1A PTEN SMARCA2 SMARCA4
2 muscle MP:0005369 9.61 ARID1A ARID1B HNF1B PIK3CA PTEN SMARCA2
3 mortality/aging MP:0010768 9.47 ARID1A ARID1B HNF1B MIR424 MIR9-1 PBRM1

Drugs & Therapeutics for Ovarian Clear Cell Carcinoma

Drugs for Ovarian Clear Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 39)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 3 216974-75-3 135329020
2
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
3
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
4
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
5
Gemcitabine Approved Phase 3 95058-81-4, 122111-03-9 60750
6
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
7
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
8 Angiogenesis Inhibitors Phase 3
9 Antineoplastic Agents, Immunological Phase 3
10 Anti-Bacterial Agents Phase 3
11 Antiviral Agents Phase 3
12 Albumin-Bound Paclitaxel Phase 3
13 Anti-Infective Agents Phase 3
14 Antimitotic Agents Phase 3
15 Antimetabolites Phase 3
16 Tubulin Modulators Phase 3
17 Antibiotics, Antitubercular Phase 3
18 Liposomal doxorubicin Phase 3
19 Immunosuppressive Agents Phase 3
20 Taxane Phase 3 108169
21 Immunologic Factors Phase 3
22
Durvalumab Approved, Investigational Phase 2 1428935-60-7
23
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60699 60700
24
Nintedanib Approved Phase 2 656247-17-5 135423438 9809715
25
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
26
Lenvatinib Approved, Investigational Phase 2 417716-92-8 9823820
27
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
28
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 2 133585-56-5, 60-18-4, 556-02-5 1153 6057
29 topoisomerase I inhibitors Phase 2
30 Protein Kinase Inhibitors Phase 2
31 Tin Fluorides Phase 2
32
Levoleucovorin Approved, Experimental, Investigational Phase 1 68538-85-2, 58-05-9, 73951-54-9 149436 6006
33
Folic acid Approved, Nutraceutical, Vet_approved Phase 1 59-30-3 6037
34 Folic Acid Antagonists Phase 1
35 Folate Phase 1
36 Vitamin B9 Phase 1
37 Vitamin B Complex Phase 1
38 Immunoglobulins Phase 1
39 Antibodies Phase 1

Interventional clinical trials:

(show all 14)
# Name Status NCT ID Phase Drugs
1 A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Platinum-doublet Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (OnPrime, GOG-3076) Recruiting NCT05281471 Phase 3 Platinum chemotherapy: carboplatin (preferred) or cisplatin;Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin;Bevacizumab (or biosimilar)
2 A Multicentre Phase II Randomised Trial of Durvalumab (MEDI4736) Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas (MOCCA) Unknown status NCT03405454 Phase 2 durvalumab;standard chemotherapy
3 A Randomised Phase II Study Of Nintedanib (BIBF1120) Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium Unknown status NCT02866370 Phase 2 Nintedanib;Paclitaxel;Pegylated Liposomal Doxorubicin (PLD);Topotecan;Carboplatin;Doxorubicin
4 Evaluation of the Efficacy of Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma Completed NCT01824615 Phase 2 Sunitinib
5 Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas Completed NCT01914510 Phase 2 ENMD-2076
6 A Phase II Evaluation of SU11248 (Sunitinib Malate) (NSC #736511) in the Treatment of Persistent or Recurrent Clear Cell Ovarian Carcinoma Completed NCT00979992 Phase 2 Sunitinib Malate
7 Sintilimab Plus Bevacizumab in Patients With Recurrent/Persistent Ovarian Clear Cell Carcinoma Recruiting NCT04735861 Phase 2 Sintilimab;Bevacizumab Biosimilar IBI305
8 A Phase II Trial of Pembrolizumab and Lenvatinib in Patients With Recurrent or Persistent Clear Cell Carcinoma of the Ovary Recruiting NCT05296512 Phase 2 Lenvatinib;Pembrolizumab
9 A Phase 1b Dose-escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects With Advanced Malignancies Completed NCT03297424 Phase 1 PLX2853
10 A Phase I Study of Safety, Pharmacokinetic and Efficacy of Orally Administered APG-5918 in Patients With Advanced Solid Tumors or Hematologic Malignancies Recruiting NCT05415098 Phase 1 APG-5918
11 First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours Not yet recruiting NCT05498597 Phase 1 AMT-151
12 A Phase l Open-Label, Dose Escalation and Cohort Expansion Study, to Assess the Safety and Activity of the Antibody-Drug Conjugate CDX-014 in Advanced or Metastatic Renal Cell Carcinoma (RCC) and Advanced or Metastatic Ovarian Clear Cell Carcinoma (OCCC) Terminated NCT02837991 Phase 1 CDX-014
13 Asian Multicenter Prospective Study of Circulating Tumor DNA Sequencing: A-TRAIN Recruiting NCT05099978
14 Exploratory Clinical Study of Camrelizumab in Combination With Anlotinib in the Treatment of Patients With Advanced Ovarian Clear Cell Carcinoma Not yet recruiting NCT05600998 Camrelizumab

Search NIH Clinical Center for Ovarian Clear Cell Carcinoma

Genetic Tests for Ovarian Clear Cell Carcinoma

Anatomical Context for Ovarian Clear Cell Carcinoma

Organs/tissues related to Ovarian Clear Cell Carcinoma:

MalaCards : Ovary, Lymph Node, Cervix, Breast, Kidney, T Cells, Endothelial

Publications for Ovarian Clear Cell Carcinoma

Articles related to Ovarian Clear Cell Carcinoma:

(show top 50) (show all 756)
# Title Authors PMID Year
1
The proteome of clear cell ovarian carcinoma. 62
36031730 2022
2
The worsening impact of programmed cell death ligand 1 in ovarian clear cell carcinomas. 62
35507079 2022
3
Patients with stage IA ovarian clear cell carcinoma do not require chemotherapy following surgery. 62
36416131 2022
4
MEX3A mediates p53 degradation to suppress ferroptosis and facilitate ovarian cancer tumorigenesis. 62
36354374 2022
5
Management of patients with early-stage ovarian clear cell carcinoma: risk stratification and fertility conservation. 62
36368707 2022
6
Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes. 62
35816189 2022
7
Loss of Major Histocompatibility Complex Class I, CD8+ Tumor-infiltrating Lymphocytes, and PD-L1 Expression in Ovarian Clear Cell Carcinoma. 62
36221308 2022
8
Endometriosis-associated mesenchymal stem cells support ovarian clear cell carcinoma through iron regulation. 62
36219681 2022
9
Complete remission of ovarian clear cell carcinoma achieved after pseudoprogression during PD-1 inhibitor therapy. 62
36043370 2022
10
Immunohistochemical and molecular analysis of an α-fetoprotein-producing cervical adenocarcinoma with clear cell morphology. 62
36183278 2022
11
Impact of bevacizumab and secondary cytoreductive surgery on survival outcomes in platinum-sensitive relapsed ovarian clear cell carcinoma: A multicenter study in Korea. 62
35863991 2022
12
Pathologic complete response to immune checkpoint inhibitor in a stage IIIB ovarian clear cell carcinoma patient with POLE mutation resistant to platinum-based chemotherapy: a case report. 62
36221285 2022
13
Clinical analysis and literature review of a case of ovarian clear cell carcinoma with PIK3CA gene mutation: A case report. 62
36123851 2022
14
Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series. 62
35545291 2022
15
Ovarian clear cell carcinoma arising in a large endometrioma - A case report with pathological correlation and literature review. 62
35694637 2022
16
The value of 'raspberry bodies' in intraoperative cytologic evaluation of adnexal masses for the diagnosis of clear cell carcinoma of the ovary: A cytological-pathological correlation. 62
35417803 2022
17
Lipophagy-ICAM-1 pathway associated with fatty acid and oxygen deficiencies is involved in poor prognoses of ovarian clear cell carcinoma. 62
35449452 2022
18
Activity-based protein profiling reveals active serine proteases that drive malignancy of human ovarian clear cell carcinoma. 62
35716777 2022
19
GLS1 is a protective factor in patients with ovarian clear cell carcinoma and its expression does not correlate with ARID1A-mutated tumors. 62
36082022 2022
20
A clearer view on ovarian clear cell carcinoma. 62
34404331 2022
21
Sonographic features differentiating early-stage ovarian clear cell carcinoma from endometrioma with atypical features. 62
35836288 2022
22
Exosomal MicroRNA as Biomarkers for Diagnosing or Monitoring the Progression of Ovarian Clear Cell Carcinoma: A Pilot Study. 62
35745075 2022
23
Trends in the risk of second primary malignancies among survivors of ovarian clear cell carcinoma. 62
35165750 2022
24
PHOSPHATE exporter XPR1/SLC53A1 is required for the tumorigenicity of epithelial ovarian cancer. 62
35377528 2022
25
Necrotizing Fasciitis In A Patient with Metastatic Clear Cell Ovarian Carcinoma Treated with Bevacizumab. 62
35751369 2022
26
Integrative genomic and transcriptomic analysis reveals immune subtypes and prognostic markers in ovarian clear cell carcinoma. 62
35043008 2022
27
Friend or foe? The prognostic role of endometriosis in women with clear cell ovarian carcinoma. A UK population-based cohort study. 62
34468823 2022
28
Sintilimab combined with bevacizumab in relapsed/persistent ovarian clear cell carcinoma (INOVA): an investigator-initiated, multicentre clinical trial-a study protocol of clinical trial. 62
35613822 2022
29
Caveolin-1-ACE2 axis modulates xenobiotic metabolism-linked chemoresistance in ovarian clear cell carcinoma. 62
35622184 2022
30
CRISPR/Cas9 Screening for Identification of Genes Required for the Growth of Ovarian Clear Cell Carcinoma Cells. 62
35723366 2022
31
The frequency and clinical implication of mismatch repair protein deficiency in Chinese patients with ovarian clear cell carcinoma. 62
35461222 2022
32
Differential roles of the Wip1-p38-p53 DNA damage response pathway in early/advanced-stage ovarian clear cell carcinomas. 62
35490254 2022
33
Immune-related gene expression signatures: a step forward in the stratification of patients with ovarian clear cell carcinoma†. 62
34908168 2022
34
Therapeutic Strategies Focused on Cancer-Associated Hypercoagulation for Ovarian Clear Cell Carcinoma. 62
35565252 2022
35
Predicting Long-Term Prognoses and Grading Platinum Sensitivity Using a Novel Progression-Free Interval Criterion in Ovarian Clear Cell Carcinoma: A Multi-Institutional Cohort Study. 62
35406519 2022
36
Adjuvant taxane plus platinum chemotherapy for stage I ovarian clear cell carcinoma with complete surgical staging: are more than three cycles necessary? 62
34779959 2022
37
The splicing factor DHX38/PRP16 is required for ovarian clear cell carcinoma tumorigenesis, as revealed by a CRISPR-Cas9 screen. 62
34965029 2022
38
Prognostic and Theranostic Biomarkers in Ovarian Clear Cell Carcinoma. 62
33770057 2022
39
Evaluation of Saccharomyces cerevisiae-like 1 (SEC14L1) in Gynecologic Malignancies Shows Overexpression in Endometrial Serous Carcinoma. 62
35283446 2022
40
Twenty-eight months progression-free survival after pyrotinib therapy for HER2-positive recurrent ovarian clear cell carcinoma: a case report. 62
35433993 2022
41
Incidence and predictive factors for recurrent clear cell ovarian carcinoma: results from a single center in Thailand. 62
35193175 2022
42
PDIA4 promotes glioblastoma progression via the PI3K/AKT/m-TOR pathway. 62
35131603 2022
43
Ovarian Clear Cell Carcinoma and Mature Cystic Teratoma Transformed to PNET and Carcinosarcoma: A Case Report with an Immunohistochemical Investigation. 62
35327349 2022
44
Intense 68Ga-FAPI-46 Activity in Lesions of Recurrent Ovarian Clear Cell Carcinoma That Were Negative on FDG PET/CT Study. 62
35006122 2022
45
Sensitive New Assay System for Serum Wisteria floribunda Agglutinin-Reactive Ceruloplasmin That Distinguishes Ovarian Clear Cell Carcinoma from Endometrioma. 62
35044763 2022
46
Everolimus combined with 5-aza-2-deoxycytidine generated potent anti-tumor effects on ovarian clear cell cancer stem-like/spheroid cells by inhibiting the COL6A3-AKT-mTOR pathway. 62
35530273 2022
47
Hypoxia-induced Maspin Expression Affects the Prognosis of Ovarian Clear Cell Carcinoma. 62
34972717 2022
48
Trends in the Incidence and Survival Rates of Primary Ovarian Clear Cell Carcinoma Compared to Ovarian Serous Carcinoma in Korea. 62
35463304 2022
49
Ovarian Clear Cell Carcinoma with Functioning Stroma and Associated Endometrial Intraepithelial Neoplasia. 62
35845973 2022
50
OSI-906 restores the sensitivity of ovarian clear cell carcinoma to cisplatin by targeting the IGF1R/AKT pathway. 62
34982265 2022

Variations for Ovarian Clear Cell Carcinoma

Copy number variations for Ovarian Clear Cell Carcinoma from CNVD:

6 (show top 50) (show all 427)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13831 1 1 88452 Loss Ovarian clear cell carcinoma
2 14094 1 103933871 104104913 Loss Ovarian clear cell carcinoma
3 14228 1 105814888 105835737 Loss Ovarian clear cell carcinoma
4 14767 1 110029012 110047636 Gain Ovarian clear cell carcinoma
5 14768 1 110029027 110046508 Loss Ovarian clear cell carcinoma
6 15067 1 112489835 112507466 Gain Ovarian clear cell carcinoma
7 15068 1 112491838 112507466 Loss Ovarian clear cell carcinoma
8 18079 1 143856437 146851948 Gain Ovarian clear cell carcinoma
9 18686 1 147137550 147788457 Gain Ovarian clear cell carcinoma
10 18898 1 147703455 147884062 Loss Ovarian clear cell carcinoma
11 18938 1 147964875 159663147 Gain Ovarian clear cell carcinoma
12 18939 1 147964875 159663147 Gain Ovarian clear cell carcinoma
13 19585 1 150821801 150857105 Loss Ovarian clear cell carcinoma
14 19705 1 151026303 151040528 Loss Ovarian clear cell carcinoma
15 21673 1 16022491 16026775 Gain Ovarian clear cell carcinoma
16 21674 1 16024203 16038247 Loss Ovarian clear cell carcinoma
17 22558 1 167482724 167509012 Loss Ovarian clear cell carcinoma
18 22559 1 167482724 167521488 Gain Ovarian clear cell carcinoma
19 22780 1 16889448 16921459 Gain Ovarian clear cell carcinoma
20 24231 1 177344731 177346824 Loss Ovarian clear cell carcinoma
21 24465 1 180956979 181720785 Gain Ovarian clear cell carcinoma
22 25838 1 194981485 195068682 Gain Ovarian clear cell carcinoma
23 25839 1 194981485 195083340 Loss Ovarian clear cell carcinoma
24 26133 1 197378133 197380848 Loss Ovarian clear cell carcinoma
25 26790 1 202780704 202781223 Loss Ovarian clear cell carcinoma
26 27522 1 209500000 222100000 Amplification CENPF Ovarian clear cell carcinoma
27 28170 1 219471 557615 Gain Ovarian clear cell carcinoma
28 28576 1 223563323 234670833 Gain Ovarian clear cell carcinoma
29 29195 1 228800000 234600000 Amplification TARBP1 Ovarian clear cell carcinoma
30 29315 1 230223390 230231832 Loss Ovarian clear cell carcinoma
31 29845 1 236917532 236921700 Loss Ovarian clear cell carcinoma
32 29954 1 238458352 238460749 Loss Ovarian clear cell carcinoma
33 30919 1 246707804 246877268 Gain Ovarian clear cell carcinoma
34 30947 1 246804059 246863823 Loss Ovarian clear cell carcinoma
35 31115 1 25455917 25517758 Gain Ovarian clear cell carcinoma
36 31116 1 25455917 25534075 Loss Ovarian clear cell carcinoma
37 32697 1 38901189 38907774 Gain Ovarian clear cell carcinoma
38 36176 1 72522942 72600553 Loss Ovarian clear cell carcinoma
39 36192 1 72535947 72584491 Gain Ovarian clear cell carcinoma
40 37128 1 85775755 85782373 Loss Ovarian clear cell carcinoma
41 37531 1 92007142 92023072 Loss Ovarian clear cell carcinoma
42 39168 10 11150202 11151804 Loss Ovarian clear cell carcinoma
43 41309 10 15959139 15974926 Loss Ovarian clear cell carcinoma
44 41503 10 19683194 19835050 Loss Ovarian clear cell carcinoma
45 41826 10 24415258 24418944 Gain Ovarian clear cell carcinoma
46 41827 10 24415258 24420691 Loss Ovarian clear cell carcinoma
47 42276 10 31286505 31291815 Loss Ovarian clear cell carcinoma
48 42716 10 3813637 3819468 Gain Ovarian clear cell carcinoma
49 42973 10 4276898 4287271 Gain Ovarian clear cell carcinoma
50 43007 10 42910287 42910797 Gain Ovarian clear cell carcinoma

Expression for Ovarian Clear Cell Carcinoma

Search GEO for disease gene expression data for Ovarian Clear Cell Carcinoma.

Pathways for Ovarian Clear Cell Carcinoma

Pathways related to Ovarian Clear Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.91 SMARCB1 SMARCA4 SMARCA2 PBRM1 H2AC18 ARID1B
2
Show member pathways
12.75 SMARCB1 SMARCA4 SMARCA2 PBRM1 H2AC18 ARID1B
3 12.24 SMARCB1 SMARCA4 SMARCA2 ARID1A
4
Show member pathways
11.98 SMARCB1 SMARCA4 SMARCA2 ARID1A
5
Show member pathways
11.77 SMARCB1 SMARCA4 SMARCA2 ARID1B ARID1A
6 11.74 TP53 PTEN PIK3CA
7 11.71 TP53 PTEN PIK3CA
8
Show member pathways
11.62 SMARCA2 SMARCA4 SMARCB1 TP53
9 11.57 TP53 PTEN PPP2R1A
10 11.55 TP53 PTEN PIK3CA
11 11.5 TP53 MIR424 MIR21
12
Show member pathways
11.42 TP53 PTEN PIK3CA
13
Show member pathways
11.4 SMARCB1 SMARCA4 SMARCA2 ARID1B ARID1A
14 11.15 TP53 SMARCA2 PTEN PIK3CA ARID1A
15
Show member pathways
11.09 SMARCB1 SMARCA4 ARID1B ARID1A
16 10.74 SMARCB1 SMARCA4
17 10.68 SMARCB1 SMARCA4 SMARCA2 PBRM1 ARID1B ARID1A

GO Terms for Ovarian Clear Cell Carcinoma

Cellular components related to Ovarian Clear Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 chromatin GO:0000785 10.4 TP53 SMARCB1 SMARCA4 SMARCA2 PBRM1 HNF1B
2 nuclear matrix GO:0016363 10.08 PBRM1 SMARCA4 SMARCB1 TP53
3 nBAF complex GO:0071565 10.07 ARID1A ARID1B SMARCA2 SMARCA4 SMARCB1
4 SWI/SNF complex GO:0016514 10.03 ARID1A ARID1B PBRM1 SMARCA2 SMARCA4 SMARCB1
5 npBAF complex GO:0071564 10.02 SMARCB1 SMARCA4 SMARCA2 ARID1B ARID1A
6 brahma complex GO:0035060 10.01 SMARCB1 SMARCA2 ARID1B ARID1A
7 RSC-type complex GO:0016586 9.91 SMARCB1 SMARCA4 PBRM1
8 bBAF complex GO:0140092 9.85 SMARCB1 SMARCA4 SMARCA2 ARID1B ARID1A
9 germ cell nucleus GO:0043073 9.76 TP53 SMARCB1
10 DNA packaging complex GO:0044815 9.35 SMARCB1 SMARCA4 SMARCA2 ARID1B ARID1A
11 SWI/SNF superfamily-type complex GO:0070603 9.02 SMARCB1 SMARCA4 SMARCA2 ARID1B ARID1A

Biological processes related to Ovarian Clear Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 nervous system development GO:0007399 10.34 ARID1A ARID1B ESS2 PTEN SMARCA2 SMARCA4
2 negative regulation of cell population proliferation GO:0008285 10.27 TP53 SMARCB1 SMARCA2 PTEN PBRM1 MIR9-1
3 chromatin remodeling GO:0006338 10.23 SMARCB1 SMARCA4 SMARCA2 PBRM1 ARID1B ARID1A
4 positive regulation of cell differentiation GO:0045597 10.21 ARID1A ARID1B PBRM1 SMARCA2 SMARCA4 SMARCB1
5 negative regulation of cell growth GO:0030308 10.18 TP53 SMARCA4 SMARCA2 PPP2R1A
6 regulation of G1/S transition of mitotic cell cycle GO:2000045 10.18 SMARCB1 SMARCA4 SMARCA2 PBRM1 ARID1B ARID1A
7 positive regulation of myoblast differentiation GO:0045663 10.15 ARID1A ARID1B PBRM1 SMARCA2 SMARCA4 SMARCB1
8 positive regulation of double-strand break repair GO:2000781 10.1 SMARCB1 SMARCA4 SMARCA2 PBRM1 ARID1B ARID1A
9 positive regulation of stem cell population maintenance GO:1902459 10.08 ARID1A SMARCA2 SMARCA4 SMARCB1
10 negative regulation of gene expression GO:0010629 10.06 TP53 PIK3CA MIR9-1 MIR509-1 MIR21
11 positive regulation of T cell differentiation GO:0045582 10.03 ARID1A ARID1B PBRM1 SMARCA2 SMARCA4 SMARCB1
12 transcription initiation-coupled chromatin remodeling GO:0045815 10.02 TP53 ARID1B ARID1A
13 nucleosome disassembly GO:0006337 10.01 SMARCB1 SMARCA4 ARID1A
14 chromatin organization GO:0006325 9.99 SMARCB1 SMARCA4 SMARCA2 PBRM1 ARID1B ARID1A
15 regulation of mitotic metaphase/anaphase transition GO:0030071 9.93 SMARCB1 SMARCA4 SMARCA2 PBRM1 ARID1B ARID1A
16 positive regulation of glucose mediated signaling pathway GO:1902661 9.86 SMARCA4 SMARCB1
17 negative regulation of NIK/NF-kappaB signaling GO:1901223 9.74 MIR9-1 MIR508 MIR21
18 regulation of nucleotide-excision repair GO:2000819 9.73 ARID1A ARID1B PBRM1 SMARCA2 SMARCA4 SMARCB1
19 negative regulation of xenobiotic detoxification by transmembrane export across the plasma membrane GO:1905700 9.59 MIR9-1 MIR508
20 regulation of G0 to G1 transition GO:0070316 9.4 SMARCB1 SMARCA4 SMARCA2 PBRM1 ARID1B ARID1A

Molecular functions related to Ovarian Clear Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 10.11 ZNF217 TP53 SMARCB1 SMARCA4 SMARCA2 PBRM1
2 transcription coactivator activity GO:0003713 9.96 SMARCB1 SMARCA4 SMARCA2 ARID1B ARID1A
3 mRNA 3'-UTR binding GO:0003730 9.43 TP53 MIR9-1 MIR508 MIR424 MIR21
4 mRNA base-pairing translational repressor activity GO:1903231 9.02 MIR9-1 MIR509-1 MIR508 MIR424 MIR21

Sources for Ovarian Clear Cell Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....